Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

a-s medication solutions - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt), fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - salmeterol 50 ug - advair diskus is indicated for the twice-daily treatment of asthma in patients aged 4 years and older. advair diskus should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ics) or whose disease warrants initiation of treatment with both an ics and long-acting beta2 -adrenergic agonist (laba). important limitation of use advair diskus is not indicated for the relief of acute bronchospasm. advair diskus 250/50 is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. advair diskus 250/50 is also indicated to reduce exacerbations of copd in patients with a history of exacerbations. advair diskus 250/50 twice daily is the only approved dosage for the treatment of copd because an efficacy advantage of the higher strength advair diskus 500/50 over advair diskus 250/50 has not been demonstrated. important limitatio

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

prasco laboratories - fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u), salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt) - fluticasone propionate and salmeterol hfa is indicated for treatment of asthma in adult and adolescent patients aged 12 years and older. fluticasone propionate and salmeterol hfa should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ics) or whose disease warrants initiation of treatment with both an ics and long-acting beta2 -adrenergic agonist (laba). limitations of use fluticasone propionate and salmeterol hfa is not indicated for the relief of acute bronchospasm. fluticasone propionate and salmeterol hfa is contraindicated in the following conditions: risk summary there are insufficient data on the use of fluticasone propionate and salmeterol hfa or individual monoproducts, fluticasone propionate and salmeterol xinafoate, in pregnant women. there are clinical considerations with the use of fluticasone propionate and salmeterol hfa in pregnant women. (see clinical considerations.) in animals, teratogenicity characteristic of cortic

Kenya - Inggeris - Pharmacy and Poisons Board

sandoz gmbh kundl biochemiestrasse 106250. austria. - salmeterol (as salmeterol xinafoate) +… - inhalation powder, pre-dispensed - 50 micrograms of salmeterol (as salmeterol… - salmeterol and fluticasone

Kenya - Inggeris - Pharmacy and Poisons Board

sandoz gmbh kundl biochemiestrasse 106250. austria. - salmeterol (as salmeterol xinafoate) +… - inhalation powder, pre-dispensed - 50 micrograms of salmeterol (as salmeterol… - salmeterol and fluticasone

Yunani - Greek - Εθνικός Οργανισμός Φαρμάκων

cipla europe n.v., antwerp, belgium - salmeterol xinafoate, ΠΡΟΤΙΜΗΤΙΚΗ Φλουτουκασόνη - ΕΝΑΙΩΡΗΜΑ ΓΙΑ ΕΙΣΠΝΟΗ ΥΠΟ ΠΙΕΣΗ - (25+250)mcg/dose - ineof00329 - salmeterol xinafoate - 36.320000 mcg; 0080474142 - fluticasone propionate - 250.000000 mcg - salmeterol and fluticasone

Cyprus - Greek - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

viatris limited (0000011780) damastown industrial park, mulhuddart, dublin 15 - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - 25mcg/250mcg - salmeterol xinafoate (8000001995) 0,0363mg; fluticasone propionate (8000031552) 0,25mg

Cyprus - Greek - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

viatris limited (0000011780) damastown industrial park, mulhuddart, dublin 15 - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - 25mcg/125mcg - salmeterol xinafoate (8000001995) 0,0363mg; fluticasone propionate (8000031552) 0,125mg

Jerman - Jerman - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

aliud pharma gmbh (3270510) - salmeterolxinafoat; fluticason-17-propionat - einzeldosiertes pulver zur inhalation - salmeterolxinafoat (26167) 0,0055 milligramm; fluticason-17-propionat (23857) 0,0189 milligramm

Jerman - Jerman - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

aliud pharma gmbh (3270510) - salmeterolxinafoat; fluticason-17-propionat - einzeldosiertes pulver zur inhalation - salmeterolxinafoat (26167) 0,0055 milligramm; fluticason-17-propionat (23857) 0,0075 milligramm

Jerman - Jerman - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

aliud pharma gmbh (3270510) - salmeterolxinafoat; fluticason-17-propionat - einzeldosiertes pulver zur inhalation - salmeterolxinafoat (26167) 0,0055 milligramm; fluticason-17-propionat (23857) 0,0379 milligramm